A Phase 3 interventional study of Ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, sponsored by Hoffmann-La Roche. Completed at 163 sites in 17 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2022-01-27.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting — 2 open to participants now, 5 under way, 3 of them phase 3. ocrelizumab · Multiple Sclerosis, Relapsing-Remitting.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, this one is the 3rd largest by enrollment, is one of 2 that started in 2016, is one of 6 in phase 3, and was the 3rd registered.
618 studies on the registry are indexed under Multiple Sclerosis, Relapsing-Remitting; 83 are open to participants now.
Browse Multiple Sclerosis, Relapsing-Remitting studies →2 of the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting are open now, in 2 countries. Recruiting first, the newest first:
Celltrion · Sites in Poland
Ages 18–55
University of California, San Francisco · Sites in United States
Ages 18–65
By country, each count listing its studies:
ocrelizumab: first FDA approval 2017 (OCREVUS), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 60 Multiple Sclerosis, Relapsing-Remitting studies recruiting now, 11 (18%) set no upper age limit and 43 (72%) stop at 75 or younger; 2 take children under 18; 11 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 2 started in 2016.
This study's enrollment of 681 is above the median of 66 across 437 interventional studies indexed under Multiple Sclerosis, Relapsing-Remitting.
Median enrollment 404 across the 10 interventional studies. Of the 5 that completed or were terminated, 5 (100%) have results posted.
This tab as a report to print or save as PDF → With an account.
7 of 10 have an industry lead sponsor. The 6 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche: 2 open now, 5 under way, 2 of them phase 3. Of 8 finished, 5 (63%) have results posted.
Among the 14 studies in Multiple Sclerosis, Relapsing-Remitting by Hoffmann-La Roche, this one is the 3rd largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2016, is one of 6 in phase 3, and was the 7th registered.
Hoffmann-La Roche’s Multiple Sclerosis, Relapsing-Remitting studies by the year they started, since 2004.
3 of the studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05906992Phase 3CelltrionA Study to Compare Efficacy, Pharmacokinetics, Pharmacodynamics and Safety of CT-P53 and Ocrevus in Patients With Relapsing-remitting Multiple Sclerosis | 2027-02 |
| NCT05296161Amsterdam UMC, location VUmcB Cell Tailored Ocrelizumab Versus Standard Ocrelizumab in Relapsing Remitting Multiple Sclerosis | 2027-02 |
| NCT06495593University of California, San FranciscoEffects of Ocrelizumab Treatment on Immune Cells in Lymph Nodes in Multiple Sclerosis | 2027-06-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 10 studies testing ocrelizumab in Multiple Sclerosis, Relapsing-Remitting, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Hoffmann-La Roche’s 14 in Multiple Sclerosis, Relapsing-Remitting:
This tab as a report to print or save as PDF → With an account.
The purpose of this prospective, multicenter, open-label, efficacy, and safety study is to assess the efficacy and safety of ocrelizumab in participants with Relapsing Remitting Multiple Sclerosis (RRMS) who have had a suboptimal response to an adequate course of a Disease-Modifying Treatment (DMT). The study will consist of a Screening period (up to 4 weeks), an Open-label treatment period (96 weeks; with last dose administered at Week 72), and a Follow-up period of at least 2 years.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
Biological: Ocrelizumab
Ocrelizumab will be administered as two 300 mg IV infusions on Days 1 and 15 followed by one 600 mg IV infusions administered at Weeks 24, 48, and 72.
Also known as: RO4964913
Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period
A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan
Time frame: Week 96
Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 24 Weeks Period
A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan
Time frame: Baseline up to 24 weeks
Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 48 Weeks Period
A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan
Time frame: Baseline up to 48 weeks
Time to First Protocol-Defined Event of Disease Activity
The definition of a protocol-defined event of disease activity is the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse defined as: Symptoms must persist for \>24 hours and should not be attributable to confounding clinical factors; Symptoms should be preceded by neurological stability for at least 30 days; Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment * 24 weeks confirmed disability progression based on increases in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan.
Time frame: Baseline up to 96 Weeks
Change From Baseline to Week 96 in Expanded Disability Status Scale (EDSS)
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.
Time frame: Baseline, Weeks: 24, 48, 72, 96
Absolute Change From Baseline in EDSS Category at Week 96
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.
Time frame: Up to Week 96
Percentage of Participants With a Baseline EDSS Score ≥2 With CDI at Week 96
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.
Time frame: Week 96
Annualized Protocol-defined Relapse Rate at Week 96
Time frame: Week 96
Time to Onset of 24-week Confirmed Disability Progression
Time frame: Baseline up to 96 Weeks
Time to Onset of First Protocol-Defined Relapse
A protocol-defined multiple sclerosis (MS) relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: * Symptoms must persist for \>24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) * Symptoms should be preceded by neurological stability for at least 30 days * Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment, consistent with an increase of at least: * ≥ 0.5 points on EDSS scale * or ≥ 2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual * or ≥ 1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual
Time frame: Baseline up to 96 Weeks
Time to Onset of First New and/or Enlarging T2 Lesion
Time frame: Baseline up to 96 Weeks
Mean Number of T1 Gd-enhancing Lesions Per MRI Scan at Weeks 24, 48 and 96
Mean number of T1 Gd-enhancing lesions per MRI scan: Total number of T1 Gd-enhanced lesions divided by the total number of interpretable MRI scans
Time frame: Weeks: 24, 48, 96
Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI From
Time frame: Baseline, Week 96
Percentage Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI
Time frame: Baseline, Week 96
Volume of New and/or Enlarging T2 Hyperintense Lesions Volume of Lesions Per MRI Scan at Weeks 24, 48, 96
The number of new and/or enlarging T2 lesions at week 24, 48 and 96 is calculated as the sum of the individual number of new and/or enlarging lesions at each visit. Data from other unscheduled assessments is included in this summary or analysis.
Time frame: Weeks 24, 48, 96
Mean Number of New and/or Enlarging T2 Hyperintense Lesions Per MRI Scan
Mean number of new and/or enlarging T2 hyperintense lesions per MRI scan: Total number of new and/or enlarging T2 hyperintense lesions divided by the total number of interpretable MRI scans
Time frame: Weeks 24, 48, 96
Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
Time frame: Weeks 48, 96
Percentage Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
Time frame: Weeks 48, 96
Adjusted Mean Change From Baseline at Week 48 and 96 in T1 Hypointense Lesion Volume
Time frame: Weeks 48, 96
Adjusted Mean Percentage Change From Baseline in Brain Volume
Time frame: Weeks 24, 48, 96
Adjusted Mean Percentage Change From Baseline in Cortical Grey Matter Volume
Time frame: Weeks 48, 96
Adjusted Mean Percentage Change From Baseline in White Matter Volume
Time frame: Weeks 48, 96
Mean Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score
Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span. The higher the results, the better processing speed/working memory.
Time frame: Baseline, Weeks: 48, 96
Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score
Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.
Time frame: Baseline, Weeks 48, 96
Percentage Change From Baseline in Cognitive Performance (Processing Speed/Working Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Symbol Digit Modalities Test (SDMT) Score
Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span.
Time frame: Baseline, Weeks 48, 96
Percentage Change From Baseline in Cognitive Performance (Visuospatial Memory) at Week 48 and Week 96 as Measured by the Brief International Cognitive Assessment for MS - Brief Visuospatial Memory Test-Revised (BVMT-R) Score
Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.
Time frame: Baseline, Weeks: 48, 96
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Time frame: Baseline up to to 96 weeks after the end of the Treatment Period
One additional participant was initially enrolled in error and the information provided is based on the ITT population.
| Milestone | Ocrelizumab |
|---|---|
| Started | 680 |
| Completed | 641 |
| Not completed | 39 |
| Withdrew: Adverse event | 7 |
| Withdrew: Death | 1 |
| Withdrew: Lack of efficacy | 3 |
| Withdrew: Physician decision | 2 |
| Withdrew: Pregnancy | 4 |
| Withdrew: Protocol violation | 2 |
| Withdrew: Study terminated by sponsor | 3 |
| Withdrew: Withdrawal by subject | 14 |
| Withdrew: Commercial ocrelizumab | 3 |
| Milestone | Ocrelizumab |
|---|---|
| Started | 64 |
| Completed | 14 |
| Not completed | 50 |
| Withdrew: Adverse event | 1 |
| Withdrew: Pregnancy | 1 |
| Withdrew: Withdrawal by subject | 9 |
| Withdrew: Study terminated by sponsor | 1 |
| Withdrew: Physician decision | 1 |
| Withdrew: Roll-over to a long term extension study | 1 |
| Withdrew: Commercial ocrelizumab | 36 |
A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan
| Percentage of Participants | Ocrelizumab |
|---|---|
| Percentage of Participants With No Evidence of Disease Activity (NEDA) as Per Protocol Defined Events During a 96-Week Period | 74.8 (71.3 to 78.0) |
A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan
| Percentage of Participants | Ocrelizumab |
|---|---|
| Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 24 Weeks Period | 87.1 (84.3 to 89.5) |
A protocol-defined event of disease activity was defined by the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse (PDR) * 24-week CDP based on increase in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan
| Percentage of Participants | Ocrelizumab |
|---|---|
| Percentage of Participants Free From a Protocol-Defined Event of Disease Activity During 48 Weeks Period | 82.6 (79.5 to 85.4) |
The definition of a protocol-defined event of disease activity is the occurrence of at least one of the following while on treatment with ocrelizumab: * A protocol-defined relapse defined as: Symptoms must persist for \>24 hours and should not be attributable to confounding clinical factors; Symptoms should be preceded by neurological stability for at least 30 days; Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment * 24 weeks confirmed disability progression based on increases in EDSS while on treatment with ocrelizumab * A T1 Gd-enhanced lesion after Week 8 * A new and/or enlarging T2 hyperintense lesion on MRI after Week 8 compared to the Week 8 MRI scan.
| Weeks | Ocrelizumab |
|---|---|
| Time to First Protocol-Defined Event of Disease Activity | NA (NA to NA) |
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.
| Points on scale | Ocrelizumab |
|---|---|
| Baseline | 2.09 ± 1.06 |
| Week 24 | -0.02 ± 0.64 |
| Week 48 | 0.01 ± 0.82 |
| Week 72 | -0.03 ± 0.85 |
| Week 96 | -0.01 ± 0.85 |
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Worsened (>0.5) | 13.4 |
| Stable (Change <= 0.5 and >= -0.5) | 72.2 |
| Improved (<-0.5) | 14.4 |
The EDSS is an ordinal clinical rating scale ranging from 0 (normal neurologic examination) to 10 (death due to MS) in half-point increments.
| Percentage of Participants | Ocrelizumab |
|---|---|
| Percentage of Participants With a Baseline EDSS Score ≥2 With CDI at Week 96 | 17.3 |
| Relapses per participant per year | Ocrelizumab |
|---|---|
| Annualized Protocol-defined Relapse Rate at Week 96 | 0.030 (0.023 to 0.038) |
| Weeks | Ocrelizumab |
|---|---|
| Time to Onset of 24-week Confirmed Disability Progression | NA (NA to NA) |
A protocol-defined multiple sclerosis (MS) relapse is an occurrence of new or worsening neurological symptoms attributable to MS that meets the following criteria: * Symptoms must persist for \>24 hours and should not be attributable to confounding clinical factors (e.g., fever, infection, injury, adverse reactions to medications) * Symptoms should be preceded by neurological stability for at least 30 days * Symptoms should be accompanied by new objective neurological worsening determined with a timely EDSS/ Functional Systems Score (FSS) assessment, consistent with an increase of at least: * ≥ 0.5 points on EDSS scale * or ≥ 2 points on one of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual * or ≥ 1 point on two or more of the following FSS scales: pyramidal, ambulation, cerebellar, brainstem, sensory, or visual
| Weeks | Ocrelizumab |
|---|---|
| Time to Onset of First Protocol-Defined Relapse | NA (NA to NA) |
| Weeks | Ocrelizumab |
|---|---|
| Time to Onset of First New and/or Enlarging T2 Lesion | NA (NA to NA) |
Mean number of T1 Gd-enhancing lesions per MRI scan: Total number of T1 Gd-enhanced lesions divided by the total number of interpretable MRI scans
| Lesions per scan | Ocrelizumab |
|---|---|
| Week 24 | 0.004 (0.001 to 0.014) |
| Week 48 | 0.004 (0.001 to 0.011) |
| Week 96 | NA (NA to NA) |
| mL | Ocrelizumab |
|---|---|
| Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI From | -558.6 ± 1194.6 |
| Percentage Change From Baseline | Ocrelizumab |
|---|---|
| Percentage Change From Baseline to Week 96 in Total T2 Lesion Volume Detected by Brain MRI | -8.5 ± 18.2 |
The number of new and/or enlarging T2 lesions at week 24, 48 and 96 is calculated as the sum of the individual number of new and/or enlarging lesions at each visit. Data from other unscheduled assessments is included in this summary or analysis.
| uL | Ocrelizumab |
|---|---|
| Week 24 | 21.4 ± 241.7 |
| Week 48 | 23.1 ± 510.2 |
| Week 96 | 3.7 ± 41.6 |
Mean number of new and/or enlarging T2 hyperintense lesions per MRI scan: Total number of new and/or enlarging T2 hyperintense lesions divided by the total number of interpretable MRI scans
| Lesions per scan | Ocrelizumab |
|---|---|
| Week 24 | 0.053 (0.038 to 0.075) |
| Week 48 | 0.009 (0.004 to 0.017) |
| Week 96 | 0.011 (0.006 to 0.020) |
| mL | Ocrelizumab |
|---|---|
| Week 48 | -416.5 ± 1224.3 |
| Week 96 | -528.5 ± 1144.7 |
| Percentage change from baseline | Ocrelizumab |
|---|---|
| Week 48 | -4.0 ± 149.7 |
| Week 96 | -12.5 ± 21.1 |
| mL | Ocrelizumab |
|---|---|
| Week 48 | -461.8 (-613.8 to -309.7) |
| Week 96 | -576.5 (-727.0 to -426.1) |
| Mean percentage change from baseline | Ocrelizumab |
|---|---|
| Week 24 | -0.153 (-0.259 to -0.047) |
| Week 48 | -0.445 (-0.556 to -0.334) |
| Week 96 | -0.805 (-0.940 to -0.669) |
| Mean percentage change from baseline | Ocrelizumab |
|---|---|
| Week 48 | -0.312 (-0.606 to -0.019) |
| Week 96 | -0.618 (-0.928 to -0.308) |
| Mean percentage change from baseline | Ocrelizumab |
|---|---|
| Week 48 | -0.382 (-0.609 to -0.154) |
| Week 96 | -0.745 (-0.983 to -0.507) |
Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span. The higher the results, the better processing speed/working memory.
| Correct responses over 90 seconds | Ocrelizumab |
|---|---|
| Baseline | 53.8 ± 13.0 |
| Week 48 | 2.5 ± 9.8 |
| Week 96 | 1.3 ± 10.2 |
Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.
| Points on scale | Ocrelizumab |
|---|---|
| Baseline | 25.0 ± 6.3 |
| Week 48 | -1.9 ± 5.3 |
| Week 96 | -1.5 ± 5.4 |
Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Symbol Digits Modalities Test (SDMT) is assessing processing speed/working memory. The SDMT presents a series of nine symbols, each paired with a single digit in a key at the top of a standard sheet of paper. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 sec. There is a single outcome measure - the number correct over the 90 sec time span.
| Percentage change from baseline | Ocrelizumab |
|---|---|
| Week 48 | 7.2 ± 30.8 |
| Week 96 | 4.8 ± 30.6 |
Brief International Cognitive Assessment for MS (BICAMS) is assessing cognitive processing speed and verbal and visual memory. Brief Visuospatial Memory Test-Revised (BVMT-R) is assessing visuospatial memory. In this test, six abstract designs are presented for 10 sec. The display is removed from view and patients render the stimuli via pencil on paper manual responses. Each design receives from 0 to 2 points representing accuracy and location. There are three learning trials, and the outcome measure is the total number of points earned over the three learning trials, thus the scale range is 0-36. The higher the result, the better visual/spatial memory.
| Percentage change from baseline | Ocrelizumab |
|---|---|
| Week 48 | -4.4 ± 31.1 |
| Week 96 | -2.0 ± 33.7 |
| Percentage of Participants | Ocrelizumab | Ocrelizumab Safety Follow-up |
|---|---|---|
| Any AE | 89.1 | 57.8 |
| SAE | 7.2 | 9.4 |
| Deaths | 0.1 | 0 |
| AEs leading to study drug discontinuation | 1.0 | NA |
| SAEs leading to study drug discontinuation | 0.7 | NA |
| AEs leading to dose modification/interruptionb | 15.0 | NA |
| Infusion-related reactions (IRRs) | 43.2 | 0 |
| Serious IRRs | 0.1 | 0 |
| Infections | 66.9 | 28.1 |
| Serious infections | 1.6 | 0 |
| Malignancies | 0.4 | 0 |
| Pregnancies | 0.7 | 1.5 |
Collected over From Baseline up to to 96 weeks after the end of the Treatment Period. Time frame includes the safety-follow-up period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Ocrelizumab | 1/680 (0.1%) | 49/680 (7.2%) | 531/680 (78.1%) |
| Ocrelizumab Safety Follow-up | 0/64 (0%) | 6/64 (9.4%) | 14/64 (21.9%) |
| Event | Ocrelizumab | Ocrelizumab Safety Follow-up |
|---|---|---|
| OEDEMAGastrointestinal disorders | 0/680 | 1/64 |
| HEPATITISHepatobiliary disorders | 1/680 | 1/64 |
| FACIAL BONES FRACTUREInjury, poisoning and procedural complications | 0/680 | 1/64 |
| INTERVERTEBRAL DISC PROTRUSIONMusculoskeletal and connective tissue disorders | 1/680 | 1/64 |
| ABORTION SPONTANEOUSPregnancy, puerperium and perinatal conditions | 1/680 | 1/64 |
| DEPRESSION SUICIDALPsychiatric disorders | 0/680 | 1/64 |
| ENTERITISGastrointestinal disorders | 0/680 | 1/64 |
| SINUSITISInfections and infestations | 3/680 | 0/64 |
| MULTIPLE SCLEROSIS RELAPSENervous system disorders | 3/680 | 0/64 |
| PNEUMONIAInfections and infestations | 2/680 | 0/64 |
| Event | Ocrelizumab | Ocrelizumab Safety Follow-up |
|---|---|---|
| INFUSION RELATED REACTIONInjury, poisoning and procedural complications | 294/680 | 0/64 |
| NASOPHARYNGITISInfections and infestations | 210/680 | 11/64 |
| HEADACHENervous system disorders | 154/680 | 0/64 |
| INFLUENZAInfections and infestations | 92/680 | 0/64 |
| URINARY TRACT INFECTIONInfections and infestations | 70/680 | 0/64 |
| FATIGUEGeneral disorders | 67/680 | 0/64 |
| BACK PAINMusculoskeletal and connective tissue disorders | 57/680 | 0/64 |
| ORAL HERPESInfections and infestations | 55/680 | 0/64 |
| UPPER RESPIRATORY TRACT INFECTIONInfections and infestations | 51/680 | 0/64 |
| COUGHRespiratory, thoracic and mediastinal disorders | 47/680 | 4/64 |
| Age, Continuous(Years) | Ocrelizumab |
|---|---|
| Mean | 34.2 ± 8.6 |
| Sex: Female, Male(Participants) | Ocrelizumab |
|---|---|
| Female | 436 |
| Male | 244 |
| Ethnicity (NIH/OMB)(Participants) | Ocrelizumab |
|---|---|
| Hispanic or Latino | 27 |
| Not Hispanic or Latino | 579 |
| Unknown or Not Reported | 74 |
| Race (NIH/OMB)(Participants) | Ocrelizumab |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 3 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 1 |
| White | 625 |
| More than one race | 2 |
| Unknown or Not Reported | 49 |
Showing the first 100 of 163 sites across 17 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Oct 2019, 37 months.
Results were first posted in Feb 2021, 1 year 3 months after primary completion.
Of 28 industry-sponsored phase 3 interventional studies under Multiple Sclerosis, Relapsing-Remitting, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 65. This study's 37 months is close to that.
Counting every sponsor, half of 38 studies reached it within 48 months; a quarter within 27 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ocrelizumab
Multiple Sclerosis, Relapsing-Remitting →